XERS
Xeris Biopharma Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.95
+6.21%Year over year
Reported trailing growth
- Revenue
- +36.3%
- EBITDA
- +124.4%
- EBIT
- +472.6%
- EPS
- +55.2%
- Free cash flow
- +430.1%
- Operating cash flow
- +449.9%
Forward estimates
Based on analyst estimates
- Revenue
- +35.7%
- EBITDA
- +459.9%
- EPS
- +351.8%
Three-year CAGR
- Revenue
- +38.3%
- EBITDA
- +190.8%
- EBIT
- +174.0%
- Net income
- +101.0%
- EPS
- +100.9%
- Free cash flow
- +173.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026